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Recent US Food and Drug Administration Warnings on
Hepatitis B Reactivation With Immune-Suppressing
and Anticancer Drugs: Just the Tip of the Iceberg?
Adrian M. Di Bisceglie,1 Anna S. Lok,2 Paul Martin,3 Norah Terrault,4 Robert P. Perrillo,5 and
Jay H. Hoofnagle6
Reactivation of hepatitis B in the context of immunosuppressive therapy may be severe
and potentially fatal. The US Food and Drug Administration has recently drawn attention
to the potentially fatal risk of hepatitis B reactivation in patients receiving the anti-CD20
agents ofatumumab or rituximab. This action focuses attention on the broader issue of
hepatitis B virus reactivation, which may occur with a wide variety of immunosuppressive
therapies in benign or malignant disease. This article summarizes the data behind this
issue. These data support the recommendation that all patients undergoing chemotherapy,
immunosuppressive therapy, hematopoietic stem cell transplantation, or solid organ trans-
plantation be screened for active or prior hepatitis B viral infection by testing for hepatitis
B surface antigen and the antibody to hepatitis B core antigen in serum. Those who are
found to be hepatitis B surface antigen–positive should start appropriate antiviral therapy
to prevent reactivation. Additionally, even those who have recovered from hepatitis B will
benefit from antiviral therapy in certain circumstances because of the risks associated with
a form of hepatitis B virus reactivation referred to as “reverse seroconversion.” There
remain many uncertain areas that warrant further study, and further advances will benefit
from close interactions between various medical specialties, regulatory agencies, and
researchers. Conclusions: There is good evidence to support routine screening of all
patients for hepatitis B prior to undergoing chemotherapy or immunosuppressive treat-
ment; use of prompt antiviral treatment appears to diminish the risk of severe or fatal
reactivation of hepatitis B. (HEPATOLOGY 2015;61:703-711)
O
n September 25, 2013, the US Food and
Drug Administration (FDA) issued a Drug
Safety Communication entitled “Boxed Warn-
ing and New Recommendations to Decrease Risk of
Hepatitis B Reactivation With the Immune-Suppressing
and Anticancer Drugs Arzerra (Ofatumumab) and Rit-
uxan (Rituximab).”1 This communique urges health-
care professionals to screen all patients for hepatitis B
viral (HBV) infection before starting treatment with
one of these agents. The recommendation is to test for
hepatitis B surface antigen (HBsAg) and antibody to
hepatitis B core antigen (anti-HBc) and then to consult
with hepatitis experts regarding monitoring and use of
HBV antiviral therapy if either of these tests is positive.
In patients who develop reactivation of HBV while on
therapy with ofatumumab or rituximab, that treatment
should be immediately discontinued and appropriate
treatment for hepatitis B initiated.
This article describes the background to this new
recommendation and suggests that the issue of HBV
reactivation may be an underappreciated clinical chal-
lenge that extends well beyond the use of these two
agents. This topic was explored in depth in a recent
conference sponsored by the American Association for
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the Study of Liver Disease, with support from the
American Academy of Dermatology, the American
College of Rheumatology, and the American Society of
Clinical Oncology. In addition, a review of the litera-
ture was done with the assistance of the National
Library of Medicine, searching for all articles related to
reactivation of hepatitis B. A total of 504 were identi-
fied through 2012. Each of these articles was reviewed
by one of the authors (J.H.H.), and an annotated bib-
liography was produced and distributed to the other
authors. Reactivation of HBV is known to occur with
a wide variety of immune-suppressive therapies and
may occur in the context of cancer treatment, immu-
nosuppressive therapy for autoimmune disease, and
transplantation. It is a potentially lethal condition and
yet is preventable.
HBV Reactivation: Definition and
Significance
Between 5% and 10% of the world’s population, or
approximately 350 million persons, are chronically
infected with HBV. In the United States, the preva-
lence of chronic HBV infection is far lower, approxi-
mately 0.5% in the general population; but the
prevalence is as high as 10% in some immigrant popu-
lations.2 Infection with HBV is diagnosed by the pres-
ence of circulating HBsAg, and in most patients, HBV
DNA is also detectable in serum with levels as low as
10 IU/mL and as high as several billion international
units per milliliter. All patients with HBV infection
develop anti-HBc, which persists after clearance of
HBsAg. Thus, it is an accurate and reliable marker of
current as well as previous infection with HBV. Anti-
body to HBsAg (anti-HBs), in contrast, is a marker
for immunity to hepatitis B and can be present as a
result of previous infection or successful vaccination.
Thus, the presence of anti-HBc without HBsAg or
anti-HBs indicates resolved HBV infection which still
has the potential for reactivation (Table 1).
Reactivation of hepatitis B is a rare but distinctive
syndrome defined by an abrupt, marked increase in
HBV replication usually accompanied by elevations in
serum aminotransferase levels and sometimes by jaun-
dice. Reactivation of HBV can occur spontaneously
but is more common in the setting of immune sup-
pression or cancer chemotherapy. It typically occurs in
individuals who have preexisting HBV infection with
HBsAg in serum. More rarely, reactivation occurs in
persons who have recovered from hepatitis B and have
antibodies to HBV (anti-HBc with or without anti-
HBs) and no detectable HBsAg in serum. The clinical
challenge is that HBV reactivation is not just a serolog-
ical or biochemical event. It is often associated with
clinical symptoms consistent with acute viral hepatitis
and jaundice. The illness may last for several weeks
and delay further chemotherapy by several cycles.
Reactivation may be so severe in some individuals as
to cause acute liver failure and death. The mortality
rate of reactivation of hepatitis B is reported to be as
high as 25%.3
Mechanisms of HBV Reactivation
Although the precise mechanism by which HBV
reactivation occurs is unclear, the initiating factor is
thought to be loss of immune control over viral repli-
cation. This is best understood in the context of cancer
chemotherapy. When these drugs are given, lympho-
cyte function is suppressed and many effector path-
ways, including the production of viral inhibitory
cytokines such as gamma-interferon and tumor necro-
sis factor-alpha, are inhibited.3 This permits increased
viral replication and viral protein expression on the
surface of infected hepatocytes. After cancer chemo-
therapy is discontinued or in between cycles of adminis-
tration, the immune system reconstitutes and lymphocyte
function improves. Cytotoxic T cells recognize the viral
peptide–expressing hepatocytes and cause variable degrees
of liver cell injury and necrosis.4 The clinical and labora-
tory correlates of these events are depicted in Fig. 1.
Some immunosuppressive agents directly block B-cell
function. Ofatumumab and rituximab are humanized
antibodies to CD20, a cell-surface marker on B lym-
phocytes, that block humoral immunity; but drugs
affecting other elements of the immune response may
similarly cause HBV reactivation. This is possible
because in chronic HBV infection HBV DNA persists
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within hepatocytes even in those with undetectable lev-
els of circulating HBV DNA. In patients who are sero-
negative for HBsAg but have detectable anti-HBc, HBV
DNA is rarely found in the circulation but trace
amounts are often found within the liver and can be
reactivated when the immune response is suppressed.
Historical Perspective
It was in the context of cancer chemotherapy that
HBV reactivation was first appreciated. Early case
reports demonstrated an increase in titer of HBsAg
and loss of anti-HBs. Subsequently, studies described
patients with elevations in serum aminotransferase lev-
els, sometimes with features of liver failure (jaundice,
hypoprothrombinemia, development of ascites, and
even death) accompanied by an increase in HBV
DNA levels in patients who were seropositive for
HBsAg. The problem of HBV reactivation was best
appreciated in Asia initially, presumably because of the
endemicity of HBV infection increasing the likelihood
of this complication. Several retrospective case series
described the problem, but the first prospective study
of HBV reactivation was done in Hong Kong.6 Among
100 patients undergoing chemotherapy for non-
Hodgkin’s lymphoma with a variety of chemotherapy
regimens in the pre–rituximab era, reactivation with
hepatitis was noted in 13 of 27 (48%) HBsAg-positive
individuals, in two of 45 (4%) anti-HBc-positive
patients, but in none of 28 patients with no evidence
of previous HBV infection (i.e., anti-HBc-negative).
The onset of reactivation occurred after one to five
courses of treatment. Three patients developed acute
liver failure, and the overall mortality among those
with HBV reactivation was 20%.
Subsequent reports described the phenomenon of
HBV reactivation occurring after solid organ transplan-
tation, bone marrow transplantation, and chemother-
apy for other cancers including solid tumors. The
introduction of infused biological agents with immu-
nosuppressive properties led to reports of HBV reacti-
vation in patients with benign autoimmune diseases
receiving these treatments. Reactivation of HBV has
been described in Western countries, although at a
lower frequency, presumably because of the lower prev-
alence of HBV infection in Western countries.
Scenarios in Which HBV Reactivation May
Occur (see Table 2)
Cancer Chemotherapy. In a systematic review of
prevention of HBV reactivation during chemotherapy
of HBsAg-positive patients with the antiviral agent
lamivudine, 14 studies were summarized, with 12
from China or Southeast Asia, and a total of 485 con-
trol patients with HBsAg not given prophylaxis. In
this untreated group, reactivation defined as an
increase in serum HBV DNA by at least 10-fold with
elevations in serum aminotransferase levels was noted
in 32%, liver failure in 13%, and death in 7%, giving
the best current estimate of the incidence and outcome
of HBV reactivation.3
Organ and Tissue Transplantation. Issues of
hepatitis B reactivation associated with liver transplan-
tation have been extensively studied. Thus, there is an
80% risk of recurrent hepatitis B following liver trans-
plantation for hepatitis B–associated liver disease, unless
prophylaxis is used with oral antiviral agents with or
without hepatitis B immunoglobulin. In addition, use
of a liver from a donor who has recovered from hepati-
tis B (HBsAg-negative, anti-HBc-positive) is associated
with a 50%-75% risk of infection for the recipient, a
dramatic example of reverse seroconversion, which can
also be prevented by antiviral prophylaxis (see Table 2).
Recipients of kidney or heart transplants who have
Fig. 1. Pattern of typical serological and biochemical changes asso-
ciated with HBV reactivation (based on examples in Hoofnagle5).
Abbreviations: ALT, alanine aminotransferase.
Table 1. Definitions
HBV reactivation Abrupt, marked increase in HBV replication
(HBV DNA levels) usually accompanied by
elevations in serum aminotransferase levels
Reverse seroconversion Reappearance of HBsAg in a person who
was HBsAg-negative, anti-HBc-positive
Recovered hepatitis B Seropositivity for anti-HBc without detectable
HBsAg (with or without anti-HBs)
Current HBV infection Seropositivity for HBsAg
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preexisting HBsAg also commonly experience reactiva-
tion of hepatitis B associated with their posttransplant
immunosuppression, which can be severe and result in
acute liver failure or severe, progressive chronic hepati-
tis B unless antiviral agents are used.
Hematopoietic stem cell transplantation (HSCT)
poses a special set of issues. This procedure is associ-
ated with very profound immunosuppression during
the conditioning regimen and after transplantation for
those receiving allogeneic transplants. Hepatitis B reac-
tivation is very frequent in this setting, and the rate of
reverse seroconversion (reappearance of HBsAg in a
person who was HBsAg-negative, anti-HBc-positive
prior to HSCT) is high. Reverse seroconversion is
probably the result of both profound immunosuppres-
sion as well as ablation of the preexisting immune
system and its replacement by an immune system that
is naive to hepatitis B.
The greatest risk is among patients undergoing allo-
geneic HSCT (whereas the risks in autologous trans-
plantation are similar to those in patients undergoing
intensive chemotherapy). Interestingly, it has also been
observed in several studies that HBsAg-positive recipi-
ents have spontaneously reverted to HBsAg-negative
status after transplantation from an HBV immune
donor and that this may be enhanced with HBV anti-
viral therapy.7,8
In a study from the Brigham and Women’s Hospital
in Boston, 61 patients were identified with resolved
HBV infection before transplantation (HBsAg-nega-
tive, anti-HBc-positive). Of these, 12 (20%) developed
reverse seroconversion. Reverse seroconversion often
occurred many months or years after transplantation.
The cumulative probability of reverse seroconversion
at 1, 2, and 4 years after HSCT was 9.0%, 21.7%,
and 42.9%, respectively.9
Biological Agents to Treat Autoimmune Diseases. The
use of biological therapies targeting tumor necrosis
factor-alpha has highlighted the problem of HBV reac-
tivation in patients with autoimmune diseases. Anti–
tumor necrosis factor agents are used to treat rheuma-
tologic, digestive, and dermatologic conditions, partic-
ularly rheumatoid arthritis, inflammatory bowel disease
(Crohn’s disease and ulcerative colitis), and psoriasis. A
recent systematic literature review identified reports of
257 patients with active or recovered HBV infection
treated with anti–tumor necrosis factor.10 Elevations
in serum aminotransferase levels were noted in 42%,
signs and symptoms of liver disease in 16%, reappear-
ance of HBV DNA in 39%, and death related to liver
failure in 5%. Reactivation was more frequent among
patients receiving infliximab compared to etanercept,
and reactivation was seven-fold higher among patients
who were HBsAg-positive (38%) compared to those
who were HBsAg-negative but anti-HBc-positive (5%).
Other Conditions and Drugs Associated With
HBV Reactivation. The use of high-dose corticoste-
roids carries a significant risk of HBV reactivation.11
High-dose corticosteroids are a part of the combina-
tion treatment regimen for many malignancies, partic-
ularly lymphoma; but corticosteroids alone may result
in HBV reactivation even when used in benign condi-
tions. Reactivation of HBV has been noted to occur
after transarterial chemoembolization, a procedure
used to treat localized hepatocellular carcinoma.12 In
this approach the chemotherapeutic agents are directed
at the tumor, so the doses used are typically much
smaller than when administered systematically. Finally,
HBV reactivation has been observed with antitumor
agents not thought to be particularly immunosuppres-
sive. Thus, there are isolated reports of reactivation
with imatinib and thalidomide, raising questions
regarding mechanisms by which other immunosup-
pressive agents cause HBV reactivation.13
Table 3 shows risk stratification for HBV reactiva-
tion based on intensity and type of immunosuppres-
sive therapy and baseline HBsAg and anti-HBc status.
Assessing the Severity of HBV Reactivation. The
diagnosis of HBV reactivation is made based upon
whether there is a marked rise or de novo appearance
of HBV DNA in serum. Different levels of change are
used in describing reactivation; a rise of more than 2
log10 IU/mL (100-fold) is an appropriate criterion.
Difficulties arise if there is no documentation of HBV
DNA levels before the cancer or immunosuppressive
therapy and if the previous HBsAg or antibody status
is unknown. Reactivation can be suspected in the
appropriate clinical setting—elevated serum amino-
transferase levels in the setting of positive HBsAg and
serum levels of HBV DNA more than 5 log10 IU/mL
Table 2. Common Clinical Scenarios and Drugs Associated
With Reactivation of Hepatitis B in Patients With Detectable
HBsAg or Anti-HBc
Clinical scenarios
Cancer chemotherapy
Solid organ transplantation
Bone marrow or stem cell transplantation
Immunosuppressive therapy for benign conditions (e.g., rheumatoid arthritis,
psoriasis, and inflammatory bowel disease)
Drugs associated with HBV reactivation
Corticosteroids
Conventional chemotherapeutic agents
Injectable or infused biological (e.g., anti-CD20, anti–tumor necrosis factor)
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(after initiation of cancer chemotherapy or immuno-
suppressive therapy), particularly if there is no obvious
recent source of de novo hepatitis B infection such as
sexual exposure or injection drug use. It is important
to recognize that varying degrees of HBV reactivation
may occur. Particularly in discussions of its frequency,
it is important to distinguish subclinical from clinically
apparent episodes. Thus, “silent” HBV reactivation
with an increase in HBV DNA levels without an
increase in aminotransferase levels or the appearance of
symptoms is more common (but usually missed) than
overt reactivation. Mild reactivation can be defined as
a rise in serum aminotransferase levels without jaun-
dice or symptoms, moderate by the appearance of jaun-
dice or clear symptoms of liver injury such as fatigue
or dark urine, and severe by the appearance of features
of liver failure (coagulopathy, hepatic encephalopathy,
or appearance of ascites). Severe cases may lead to
death. Therefore, prompt recognition of HBV reactiva-
tion and institution of antiviral therapy are warranted.
Approach to Screening. The Centers for Disease
Control and Prevention have long recommended HBV
screening for at-risk persons. However, large numbers
of individuals with hepatitis B remain undiagnosed. In
2008, the Centers for Disease Control and Prevention
updated their recommendations to include screening
of immigrants to the United States from intermediate
and high endemic areas.2 These recommendations
have been endorsed by the Institute of Medicine and
by the US Preventive Services Task Force.14 The Cen-
ters for Disease Control and Prevention also calls for
hepatitis B testing for all patients needing immunosup-
pressive therapy (see Table 4), and this recommenda-
tion has been endorsed by several professional
societies. Patients at risk of HBV reactivation are read-
ily identified by testing for HBsAg and anti-HBc,
which is both widely available and inexpensive.
In the case of ofatumumab and rituximab, the FDA
has recommended in a boxed warning that all patients
should be screened for HBV infection with these two
serological tests prior to using these agents. While simi-
lar recommendations have appeared within the package
inserts for these and other immunosuppressive agents in
the past, this is the first time they have been given this
prominence. The American Association for the Study of
Liver Diseases has for several years recommended rou-
tine screening for hepatitis B in patients who are at risk
of HBV infection prior to initiation of chemotherapy or
immunosuppressive treatment—this includes persons
born in areas of high or intermediate HBV prevalence
(particularly east Asia, sub-Saharan Africa, and eastern
Europe) and those with high-risk behaviors as recom-
mended by the Centers for Disease Control and Preven-
tion.2,16,17 This strategy, though more cost-effective than
universal screening, has not been effective in clinical
practice because risk factors for HBV infection are not
always assessed by providers or recognized by patients.21
Large cancer centers in the United States have moved
to screening all patients newly diagnosed with cancer
prior to therapy. A retrospective study of patients with
cancer at The University of Texas MD Anderson Can-
cer Center in 2004-2007 found that the HBV screen-
ing rate before chemotherapy was low (17%). Among
those who were screened, the prevalence of HBsAg was
1.5%, while 7.4% had anti-HBc without HBsAg. The
key predictors of HBV screening were having a history of
Table 3. Risk Stratification for HBV Reactivation
Therapy HBsAg-Positive
HBsAg-Negative,
Anti-HBc-Positive
Anti-CD20 Very high‡ Moderate
Hematopoietic stem cell transplantation
High-dose corticosteroids*
Other cytokine inhibitors (e.g., anti-CD52)
High Low
Combination cytotoxic chemotherapy† (without corticosteroids) Moderate Rare
Anti–tumor necrosis factor
Anti–rejection therapy for solid organ transplant recipients
Methotrexate
Azathioprine
Low Rare
Androgen deprivation therapy
Estrogen and progesterone blockers
No known effect No known effect
*Doses of corticosteroids in excess of 20 mg of prednisone (or equivalent) have been reported to have a high risk of HBV reactivation.
†Examples of combinations of cytotoxic therapy that have been associated with HBV reactivation include cisplatin-based chemotherapy for squamous cell carci-
noma and CHOP (cyclophosphamide [Cytoxan], hydroxydoxorubicin [Adriamycin], vincristine [Oncovin], and prednisone) for lymphoma.
‡Although reported rates of HBV reactivation vary considerably, rough estimates of very high risk could be considered to be in excess of 20%, high in the 11%-
20% range, moderate somewhere between 1% and 10%, and low less than 1%.
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HBV infection (odds ratio5 10.2, confidence interval
5.9-17.6), hematologic malignancy (odds ratio5 21.5, con-
fidence interval 18.3-25.2), and rituximab treatment (odds
ratio5 4.2, confidence interval 3.4-5.1).21
A similar retrospective analysis done at Memorial
Sloan-Kettering Cancer Center led to the institution of
universal HBV screening before immunosuppressive ther-
apy and an algorithm to guide appropriate prophylaxis in
those who test positive. This became a hospital-mandated
screening program in March 2009 (E. Ludwig, personal
communication, 2013). Since then, 12,688 patients have
been screened for HBV prior to starting chemotherapy;
78 (0.61%) were HBsAg-positive and 1039 (8.2%) were
anti-HBc-positive. At Memorial Sloan-Kettering Cancer
Center HBV screening rates have increased over time
from approximately 15% before the implementation of
mandatory screening to approaching 90% at present.
Strikingly, no cases of HBV reactivation were observed
after the implementation of that requirement.
The present authors and the American Association for
the Study of Liver Disease strongly recommend that all
patients undergoing chemotherapy, immunosuppressive
therapy, HSCT, or solid organ transplantation be screened
for active or prior HBV infection by testing for HBsAg
and anti-HBc in serum. The American Society of Clinical
Oncology has issued a provisional clinical opinion support-
ing screening patients with risk factors for HBV infection
prior to highly immunosuppressive therapy.20 Interestingly,
the MD Anderson study cited above found that case iden-
tification was substantially improved through a policy of
universal, rather than high-risk, screening.21 In addition, it
is recommended that screening of patients with inflamma-
tory bowel disease or other benign medical conditions
necessitating long-term immunosuppressive therapy for
hepatitis B be incorporated into their routine care.
Prophylactic Antiviral Therapy. Once a patient
is identified as being seropositive for HBsAg, there is
good evidence that he or she would benefit from
receiving antiviral treatment for hepatitis B before
starting chemotherapy or receiving immunosuppressive
agents. With the availability of well-tolerated orally
administered antiviral agents active against hepatitis B,
treatment or even prevention of HBV reactivation has
been possible. Lamivudine was the first such agent to
become available and, in fact, has been the agent used
in most of the clinical studies on HBV reactivation.
Lamivudine is a nucleoside analogue with potent anti-
viral activity against HBV as well as being safe, well-
tolerated, and inexpensive; the main problem with it is
the frequent emergence of resistant viral variants after
prolonged use (typically for more than 6 months).16
There have been several prospective, randomized con-
trolled trials (see Table 5) and a very large number of case
series published, demonstrating the effectiveness of lami-
vudine in preventing HBV reactivation. A systematic
review of prevention of reactivation during chemotherapy
of HBsAg-positive patients by lamivudine3 included 14
studies with 275 patients receiving lamivudine for pro-
phylaxis and 485 control patients not given lamivudine.
Lamivudine prophylaxis decreased HBV reactivation and
HBV-hepatitis by 80%-100% and eliminated HBV-liver
failure. Lamivudine prophylaxis also decreased cancer-
related mortality, probably by reducing the need for delay
or interruption of chemotherapy.
Table 4. Recommendations of Various Authoritative Bodies Regarding Screening for Hepatitis B to Mitigate the Risk of HBV
Reactivation
Organization Recommendation Tests to Be Done
Centers for Disease Control and
Prevention2
Persons needing immunosuppressive therapy, including chemotherapy,
immunosuppression related to organ transplantation, and immunosuppression for
rheumatologic or gastroenterologic disorders
HBsAg, anti-HBc, anti-HBs
American Academy of
Dermatology15
Hepatitis B reactivation after treatment with tumor necrosis factor inhibitors has
been reported; in the appropriate clinical setting, patients should be screened
for hepatitis B infection.
Not stated
American Association for the
Study of Liver Diseases16,17
All patients before beginning immunosuppressive therapy HBsAg, anti-HBc
Asian Pacific Association for the
Study of the Liver18
Before receiving immunosuppression or chemotherapy, patients should be screened
for HBsAg. Patients who are going to receive biologic agents such as anti-CD20
or anti–tumor necrosis factor-a should be screened for anti-HBc.
HBsAg, anti-HBc
European Association for the
Study of the Liver19
All candidates for chemotherapy and immunosuppressive therapy should be
screened.
HBsAg, anti-HBc
American Society of Clinical
Oncology20
Physicians may consider screening patients belonging to groups at heightened risk
for chronic HBV infection or if highly immunosuppressive therapy is
recommended.
Consider HBsAg,
consider anti-HBc
US Preventive Services Task
Force13
Screen persons who are immunosuppressed. HBsAg
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More recently, other antiviral agents with a lower risk of
antiviral drug resistance, notably tenofovir and entecavir,
have replaced lamivudine as first-line agents to treat
chronic hepatitis B.16 Emerging data show that entecavir is
safe and effective in preventing HBV reactivation in
patients receiving cancer chemotherapy and in recipients
of solid organ or stem cell transplantation. A recent
randomized controlled trial of HBsAg-negative, anti-HBc-
positive patients receiving chemotherapy that included an
anti-CD20 agent found that HBV reactivation occurred in
2% of the group that received entecavir prophylaxis com-
pared to 18% of the control group (P< 0.05).23
Despite the availability of safe and effective antiviral
agents, several questions remain, mostly about the tim-
ing of starting therapy and the appropriate duration of
therapy. If antiviral therapy is initiated after a flare of
hepatitis has already begun, it may take several months
to reduce viral levels and to control the disease. Several
randomized trials have demonstrated that prophylactic
(starting antiviral therapy prior to or at the same time
as starting chemotherapy) is more effective than pre-
emptive (starting when viral levels begin to rise) antivi-
ral therapy in preventing HBV reactivation (see Table
5) and that these preventative approaches are in turn
more effective than deferring antiviral treatment until
there is clinical evidence of hepatitis or liver failure.
Most experts agree that antiviral therapy should be
continued for the duration of chemotherapy, but there
is debate about how long to continue thereafter
because of the paucity of data on optimal duration of
therapy. Most studies have continued therapy for 3 to
6 months after the last cycle of chemotherapy, though
many experts favor continuing for up to 12 months,
particularly when anti-CD20 is used; reactivation after
stopping therapy remains a possibility, particularly in
patients who started out with high levels of viremia. In
patients with active hepatitis (elevated HBV DNA and
aminotransferase levels) prior to starting chemotherapy,
antiviral therapy may need to be administered longer
term or indefinitely. In patients who receive a solid
organ transplant or HSCT, antiviral prophylaxis may
be required long term, if not for life. Approaches using
vaccination against HBV to induce immunity and
allow discontinuation of antiviral therapy are now
being evaluated in prospective studies after HSCT.
Appropriate recommendations concerning antiviral
prophylaxis of patients who are seronegative for
HBsAg but positive for anti-HBc (i.e., recovered from
hepatitis B) are not quite as clear as those for patients
with HBsAg. Reactivation of HBV is well documented
among this category of patients. For example, the
recent Drug Safety Communication from the FDA
described reverse seroconversion (that is, reappearance
of HBsAg in a patient who had previously recovered
from hepatitis B) among 22 of the 109 cases identified
with HBV reactivation associated with use of rituxan
or ofatumumab.1 Reverse seroconversion is less fre-
quent than HBV reactivation in HBsAg-positive per-
sons and appears to occur mostly with more potent
forms of immunosuppression. Nevertheless, reverse
seroconversion may still result in severe or even fatal
liver injury. Given that HBV reactivation is less com-
mon in this situation and many more patients would
be identified by screening (approximately 4% of the
general population in the United States and >60% in
east Asia), more restricted recommendations for pro-
phylactic antiviral treatment are perhaps appropriate.
The American Association for the Study of Liver Dis-
eases recommends routine use of appropriate antiviral
therapy in all patients who are seropositive for HBsAg
prior to or at the initiation of chemotherapy, immuno-
suppressive therapy, HSCT, or solid organ transplanta-
tion (Fig. 2). For patients who are seronegative for
HBsAg but have anti-HBc in serum, we recommend
routine antiviral prophylaxis in those receiving anti-
CD20 therapies and in those undergoing HSCT or
solid organ transplantation. Monitoring and initiation
of antiviral therapy only if HBV DNA becomes detecta-
ble in serum may be appropriate for lesser degrees of
immunosuppression in patients who have recovered
from hepatitis B (i.e., HBsAg-negative, anti-HBc-posi-
tive). While the optimal monitoring interval is not clear,
Table 5. Prospective, Randomized Controlled Trials of Antiviral Therapy to Prevent HBV Reactivation
Author No. of Patients Disease and Treatment Treatment Antiviral Agent Rate of HBV Reactivation (%) P Value
Prophylactic treatment Control **
Hwang et al.21 42 Breast Chemotherapy Lamivudine 0.0 28.6 0.021
Huang et al.22 80 Lymphoma Rituximab-containing
chemotherapy
Entecavir 2.4 17.9 0.027
Lau et al.23 30 Lymphoma Chemotherapy Lamivudine 0.0 53 0.002
Hsu et al.24 52 Lymphoma Chemotherapy Lamivudine 11.5 56 0.001
Jang et al.25 76 HCC TACE Lamivudine 2.8 40.5 <0.001
*Control patients either remained untreated or had delayed treatment that began only after HBV reactivation had occurred.
Abbreviations: HCC, hepatocellular carcinoma; TACE, trans-arterial chemoembolization.
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this might range from as short as 1 month to as long as
6 months. Because of the risk of delayed reactivation,
monitoring should continue for 6 months after cessa-
tion of immunosuppressive therapy and longer in those
who underwent HSCT or received rituximab.
Summary and Conclusions
In summary, HBV reactivation is clearly an underap-
preciated clinical challenge. Recent FDA action to rec-
ommend screening of all patients for hepatitis B prior
to receiving ofatumumab or rituximab has focused
attention on this issue. All patients with active or previ-
ous HBV infection face some risk of HBV reactivation
when receiving cancer chemotherapy or immunosup-
pressive therapy, even for benign conditions. Reactiva-
tion of HBV can readily be prevented by initiating
prophylactic antiviral therapy before starting the immu-
nosuppressive regimen, and safe and effective antiviral
agents are now widely available for this purpose.
We recommend that all patients undergoing chemo-
therapy, immunosuppressive therapy, HSCT, or solid
organ transplantation be screened for active or prior
HBV infection by testing for HBsAg and anti-HBc in
serum. Those who are found to be HBsAg-positive
should start appropriate antiviral therapy with a first-
line agent prior to or at the start of the planned therapy
(Fig. 2). Because of the risk of reverse seroconversion
among those who have recovered from hepatitis B (i.e.,
those who are seronegative for HBsAg but have anti-
HBc in serum), we further recommend routine antiviral
prophylaxis if they are to be profoundly immunosup-
pressed by receiving anti-CD20 therapies or undergoing
HSCT or solid organ transplantation.
While further study will be necessary to completely
define the risks, benefits, and costs of universal screening,
we feel that the evidence as it stands now is sufficiently
compelling to make routine screening for hepatitis B a
standard practice. More information is certainly needed
with the use of minimally immunosuppressive therapies
such as hormonal therapy or newer targeted treatments.
Further research is also needed into the details of how
best to deal with the risk of reverse seroconversion.
Recent events as described above draw attention to
the need for further study of HBV reactivation. Algo-
rithms to manage those who are HBsAg-negative but
anti-HBc-positive need to be validated on a large scale.
It is likely that the number of patients treated with
immunosuppressive drug regimens will increase in the
future because novel cytokine inhibitors are already in
advanced clinical development to treat a variety of der-
matologic, rheumatologic, and other autoimmune con-
ditions.26,27 It is clearly preferable for all medical
specialties to develop uniform protocols and algo-
rithms together in consultation with regulatory agen-
cies and to identify areas of uncertainty for
collaborative research. Standardized protocols and algo-
rithms should be communicated by the specialty soci-
eties to their members as well as other physicians
involved in the care of patients who require immuno-
suppressive therapies for cancer or benign diseases.
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